AbbVie Inc. has agreed to acquire Capstan Therapeutics, a privately held biotechnology startup specializing in in vivo CAR-T cell therapies, in a deal valued at up to $2.1 billion in cash. Capstan's lead asset, CPTX2309, is a first-in-class in vivo tLNP anti-CD19 CAR-T therapy currently in Phase 1 trials, targeting B cell-mediated autoimmune diseases, fibrosis, and cancer. The acquisition is part of AbbVie's strategic push to expand its immunology portfolio with experimental treatments for autoimmune conditions. This transaction adds a novel CAR-T platform to AbbVie's pipeline, marking a move into early-stage clinical programs with potentially disruptive technology for next-generation autoimmune therapies. The deal was announced on June 30, 2025, and reflects AbbVie's commitment to advancing patient care in immunology.